In March 2019 it was announced that Oncternal Therapeutics Inc. would reverse merge through a stock-for-stock transaction with fellow cancer drug developer GTx Inc. Expected to be comleted during the Summer 2019. the resulting firm will take the Oncternal name and GTxs Nasdaq listing with symbole chnage to (NASDAQ:ONT). It was also indcayed that no GTx, employee would remain with teh firm when the transaction is fully consummated. GTx Inc had been working on drugs in the selective estrogen receptor modulator and selective androgen receptor modulator classes. Engaged in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions, the focus is on drugs that utilize hormonal pathways. the firm's major product to date is toremifene, and drugs in development include enobosarm and GTx-758. With priority on development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC), the company?'s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI.
